Ventilator-Associated Pneumonia (VAP)
Conditions
Brief summary
Evaluate efficacy and safety of prophylactic antibiotics in preventing early ventilator-associated pneumonia
Interventions
Beta lactam cefipim infusion (20mg/kg -12h -2 days ) total volume 10 ml
DRUGSalin
Patient will receive .9 % saline (10ml /12h/2days)
Sponsors
Esraa Salah Mohamed Abdallah Eladl
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Intervention model description
Efficacy of prophylactic antibiotic against vent.associated pneumonia
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* • Age \> 18 years or older * Both sexes will be included. * Invasive mechanical ventilation
Exclusion criteria
* ongoing pneumonia or gross aspiration confirmed by the presence of lung infiltrates on chest radiographs at admission before invasive ventilation * previous lung disease precluding accurate interpretation of chest radiographs * ongoing antibiotic therapy or during the week before admission * known chronic colonization with multidrug-resistant bacteria * known allergy to beta-lactam antibiotics * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ventilation associated pneumonia | from the 2nd to the 7th day of mechanical ventilation | The primary outcome is the proportion of patients who will develop VAP (radiology, TLC, temperature, hemodynamic, sputum culture )from the 2nd to the 7th day of mechanical ventilation |
Countries
Egypt
Outcome results
None listed